The National Regulator of the country, the Drugs Controller General of India (DCGI), after careful examination, has accepted the recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trial of Covaxin (COVID vaccine) in the age group 2 to 18 years, to its manufacturer Bharat Biotech Ltd on 12.05.2021.
M/s Bharat Biotech International Ltd., Hyderabad (BBIL) had proposed to carry out a Phase- II/III clinical trial of Covaxin in the age group of 2 to 18 years. The trial will be conducted in 525 healthy volunteers.
In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.
As rapid regulatory response, the proposal was deliberated in Subject Expert Committee (SEC) (COVID-19) on 11.05.2021. The Committee after detailed deliberation recommended for grant of permission to conduct proposed Phase II/III clinical trial to certain conditions.
Antibiotic use has surged globally, leading to a rise in antibiotic resistance, especially concerning in…
Choking is a leading cause of injury and death in young children, particularly those under…
Hard Water (Khara Pani) Leading To Hair Fall Hard water is rich in minerals and…
Discover how the rise in high blood pressure during pregnancy is impacting maternal and fetal…
"Discover the transformative power of six delicious homemade drinks that can help you naturally melt…
"Transform your weight loss routine with these eight delicious fat-flushing drinks that not only hydrate…